The EBV shedding and transmission occur probably through saliva after replication in the oropharyngeal epithelium. 1, 2 We have explored the possibility of an EBV survey using RQ-PCR in the saliva of solid tumour patients treated with allogeneic SCT. We assumed that in this new patient group, the reduced-intensity conditioning used would cause less preparation-related damage of cells with high turnover in the oropharynx. In addition, reducedintensity conditioning might lead to an early immune recovery and also decrease the risk of lymphoproliferative disease and lymphoma.
Twenty patients, median age 55.5 years, with metastatic solid cancer underwent allogeneic SCT as adjuvant therapy (Table 1) . The control group consisted of 10 age-and sexmatched healthy individuals. All, but one donor, was EBV positive by serology. Patients and control persons gave their informed consent to participate in this study, which was approved by the local ethics committee. Conditioning was either non-myeloablative (n ¼ 4) or of reduced-intensity (n ¼ 16) using fludarabine and 2 Gy TBI or CY, and in patients with a matched unrelated donor (MUD), ATG of 4 mg/kg (Table 1) . 3, 4 Complete donor chimerism was defined when 495% of peripheral blood CD3 þ cells were of donor origin. 5 The EBV genome load in prospectively collected saliva (2 ml; n ¼ 175) and peripheral blood (20 ml EDTA; n ¼ 177) samples was measured using RQ-PCR. 6 For results, the median number of pairs of saliva and blood samples per patient was 8 (range 4-15), and median follow-up was 266 (66-441) days after SCT. EBV DNA was detected in saliva at least once in all patients with a median of four (1-9) times. In blood, EBV DNA was found at least once in 70% (14/20) of the patients; median four (1-10) times. Thus, EBV DNA was found both in saliva and blood in 14 patients during the first post-SCT year. In 5 of these 14 patients, EBV DNA was detected in saliva before it could be found in blood with median of 30 (14-145) days of difference, whereas in 7 patients EBV DNA occurred at the same time. In all 9 MUD and 5/11 sibling (Sib) donorgrafted patients, EBV DNA was detected both in saliva and blood; it occurred first in saliva in 3 and 2 patients, respectively. EBV DNA occurred earlier in saliva in MUD patients as compared with Sib donor patients; median 33 (4-283) vs 63 (8-375) days post-SCT. In saliva and blood, the median load of virus was 60 000 (300-5 Â 10 8 ) and 6000 (1000-32 000) DNA copies/ml, respectively. The viral load in saliva was higher than in blood in 79% (26/33) of the samples obtained in parallel (Figure 1a ). There was no correlation (r 2 ¼ 0.06) between the EBV DNA load in saliva vs that in peripheral blood (Figure 1b) .
The EBV DNA was shown in saliva both in all 9 patients with ATG and 11 without ATG therapy (NS). In contrast, EBV DNA finding in blood was associated with the ATG administration; 9/9 with vs 5/11 without ATG therapy (P ¼ 0.01, Fisher's exact test). EBV DNA was found not only in the saliva of 14/20 patients who had reached complete donor chimera, but also in the remaining 6 patients with still mixed chimera at the end of the first year. In patients with EBV DNA finding both in saliva and blood (n ¼ 14), EBV genome was found in 11 patients with and in 3 without complete donor chimera (NS). Acute GVHD grade 4II developed in 70% (14/20) of the patients. EBV DNA was found in saliva in all 14 patients with and in 6 without a GVHD (NS). In addition to EBV DNA demonstration in saliva in all tumour patients, blood samples were positive in 5/8 and 6/7 patients with colorectal or renal cell cancer, respectively (NS). No post-transplant EBV-associated lymphoproliferative disease/lymphomas were diagnosed.
Seven of the ten control persons had EBV DNA in saliva with a median two positive samples of the three collected ones with two-week interval. The median load was 2 (0.14-23) Â 10 4 copies/ml. EBV DNA was not found in any blood samples of the EBV seropositive control individuals. We report here that 86% of the SCT solid-tumour patients had EBV DNA either before or at the same time in saliva as compared with blood. This was found in approximately half of the patients with Sib donor, possibly reflecting undamaged cells of salivary glands and oropharyngeal epithelium. Interestingly, all nine MUD patients were diagnosed with EBV genome in saliva and blood. The MUD patients also presented with EBV DNA earlier than Sib patients both in saliva and blood, suggesting the influence of HLA mismatch and use of ATG as known risk factors. 7 In most samples, the EBV DNA load in saliva exceeded that in blood with a median ten times in magnitude. More patients with Sib than MUD showed higher than median EBV DNA loads in saliva, but all MUD patients had higher than the median load in peripheral blood (data not presented). The discrepancy between virus production as well as release into the saliva and blood samples may mirror a different control mechanism of EBV locally in oropharynx as compared with peripheral blood upon immunosuppression and immature immunity. In patients with infectious mononucleosis, efficient control of EBV requires appropriate CD8 þ T-cell homing to oropharyngeal site. 8 Taken together, this may reflect a possibility for EBV in Sib patients to favour shedding in oropharyngeal milieu as compared with blood where the major EBV genome load of MUD patients with impaired T-cell control was found.
The median load of EBV DNA copies in saliva of the SCT patients was comparable to that found in healthy controls, suggesting a low degree of oropharyngeal damage due to reduced-intensity conditioning. Although approximately two-thirds of the patients had developed complete donor chimerism, it seemed not to protect them from the EBV DNA occurrence. We have reported earlier that the new functional immunity in solid tumour patients demand comparable time period of 12-18 months as known after total myeloablative SCT to mature. 9 None of the patients was diagnosed with clinical EBV infection or lymphoproliferative disease/lymphoma, a feared oncogenic potential of EBV.
1,2 The evolution of malignancy most likely depends on the duration of viral replication, the tissue damage as well as the level and type of immune competence.
In conclusion, there was no correlation between EBV-DNA levels in blood and saliva, nor between DNA levels in saliva and disease. Therefore, testing in saliva does not seem to add any information, and should probably not replace blood testing. 
